Judge won’t halt most integration between CVS, Aetna during merger review

The federal judge reviewing approval of CVS Health’s acquisition of Aetna said he will not require the companies to stop integrating most of their operations, according to CNBC.

Advertisement

On Dec. 18, Judge Richard J. Leon of the U.S. District Court in the District of Columbia asked CVS and Aetna to ensure some of their operations remained distinct while he continues a review of the companies’ merger. CVS completed its $70 billion acquisition of Aetna Nov. 28. However, Mr. Leon, who is tasked with reviewing the Justice Department’s antitrust settlement, has raised red flags over how the department reviewed the merger.

In an order submitted Dec. 21, Mr. Leon said he would accept CVS’ proposal to let Aetna make independent product, pricing and personnel decisions through the review, according to CNBC.

“Based on CVS’s constructive and appropriate representations, I am satisfied that, so long as these measures remain in place, the assets involved in the challenged acquisition will remain sufficiently separate (during the review period),” Mr. Leon wrote in his order, according to the report.

More articles on payer issues:
Uninsured rate among children climbs for first time in nearly 10 years
$67B Cigna acquisition of Express Scripts closes Dec. 20
ACA plan enrollment declines to 8.5 million people

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Reconsider What’s Possible: Enterprise RCM and the Pro-Fee Practice

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Garett Kreitz, Med-MetrixJohn Stefanowicz, Med-Metrix

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.